Cargando…

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klaassen, Sebastiaan HC, van Veldhuisen, Dirk J, Nienhuis, Hans LA, van den Berg, Maarten P, Hazenberg, Bouke PC, van der Meer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2020
Materias:	Cardiac Amyloidosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479537/ https://www.ncbi.nlm.nih.gov/pubmed/32944291 http://dx.doi.org/10.15420/cfr.2019.16

Ejemplares similares

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Value of the HFA‐PEFF and H(2)FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies
por: Aimo, Alberto, et al.
Publicado: (2022)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

Transthyretin Cardiac Amyloidosis: A Noninvasive Multimodality Approach to Diagnosis Using Transthoracic Echocardiography, 99m-Tc-Labeled Phosphate Bone Scanning, and Cardiac Magnetic Resonance Imaging
por: Shukla, Akhil, et al.
Publicado: (2017)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Regression of the Anatomic Cardiac Features of Amyloid Light Chain Cardiac Amyloidosis Accompanied by Normalization of Global Longitudinal Strain
por: Fitzgerald, Benjamin T., et al.
Publicado: (2017)

An Autopsy Case of Cardiac Amyloidosis with Heterogeneous Deposition of Amyloid Protein: A Possible Mechanism for Relative Apical Sparing of Longitudinal Strain
por: Sawada, Naoko, et al.
Publicado: (2019)

Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction
por: Ton, Van-Khue, et al.
Publicado: (2015)

Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan
por: Naito, Takanori, et al.
Publicado: (2023)

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
por: Jonker, Daphne L., et al.
Publicado: (2018)

Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly
por: TIAN, Zhuang, et al.
Publicado: (2020)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome
por: Ozercan, Mubin, et al.
Publicado: (2021)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value
por: Cipriani, Alberto, et al.
Publicado: (2022)

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022)

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
por: Wechalekar, Ashutosh D., et al.
Publicado: (2022)

Ruptured Bullae: A Case of Transthyretin Cardiac Amyloidosis
por: Dayco, John, et al.
Publicado: (2021)

Heart Failure With Preserved Ejection Fraction: An Evolving Understanding
por: Tah, Sunanda, et al.
Publicado: (2023)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis
por: Connolly, Mark P., et al.
Publicado: (2019)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Heart Failure With Preserved Ejection Fraction: Current Status of Daily Clinical Practice in Indonesia
por: Nauli, Siti E, et al.
Publicado: (2023)

Does early surgery result in improved long-term survival compared to watchful waiting in patients with asymptomatic severe aortic regurgitation with preserved ejection fraction?
por: Heuts, Samuel, et al.
Publicado: (2022)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

Baseline LV ejection fraction by cardiac magnetic resonance and 2D echocardiography after ST-elevation myocardial infarction – influence of infarct location and prognostic impact
por: Schwaiger, Johannes P., et al.
Publicado: (2019)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction
por: Mesquita, Evandro Tinoco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mirrj97mieo88opumk75usn4oq